Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sedation of severe COVID-19 disease are often complicated. We try to find a correlate for this observation by encephalographic studies.
Sedation of critically ill ventilated coronavirus patients, continues to be a challenging issue. Also, neurological symptoms of severe COVID-19 disease have been described frequently. Difficulties in sedation of these patients have been discussed repeatedly. The aim of this study is to investigate whether an encephalographic correlate can be found. Appropriate processed encephalographic techniques have been used for anesthesia monitoring for many years.
The aim of our study is to collect unrelated processed and raw EEG data of sedated COVID-19 patients and to investigate the correlation to the necessary sedation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| critical ill COVID-19 | Critically ill COVID-19 patients with need for ventilation and appropriate sedation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Encephalography measurement | Other | Encephalography measurement and partially aggravated sedation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Raw data encephalography measurement | Measurement of the brain activity detectable for the examination procedure in the surface encephalogram. | From the beginning of the measurement until the end of the examination (10 to 20 minutes). |
| Processed encephalography measurement | Measurement of detectable algorithm based patient sedation score based on brain activity in the surface encephalogram. | From the beginning of the measurement until the end of the examination (10 to 20 minutes). |
| Measure | Description | Time Frame |
|---|---|---|
| Dosage of continuously administered centrally acting alpha2 agonists. | Sedative dosage continuously administered during the measurement interval. [µg/kg/h] | From 90 minutes before to 10 minutes after encephalographic measurement |
| Dosage of continuously delivered central GABA receptor active substances. |
Not provided
Inclusion Criteria:
Intubated ventilated patients with SARS-CoV-2 associated acute respiratory distress syndrome and sedation difficulty.
Exclusion Criteria:
Pre-existing severe cerebral brain damage and dysfunction. For example: previous medial infarction, cerebral hemorrhage, structural epilepsy.
Not provided
Not provided
Critically ill COVID-19 patients requiring advanced intensive care treatment with existing intubation-requiring acute respiratory distress syndrome under invasive ventilation. Adequate depth of sedation is usually required for appropriate therapy, which is frequently challenging in COVID-19 patients.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Armin N Flinspach, M.D. | Goethe-University Frankfurt | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Frankfurt | Frankfurt am Main | Hesse | 60590 | Germany |
The datasets generated and/or analyzed during the current study are not publicly available due to national data protection laws. Upon justified request, the data will be accessible at the primary investigator.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D012128 | Respiratory Distress Syndrome |
| D018352 | Coronavirus Infections |
| ID | Term |
|---|---|
| D013568 | Pathological Conditions, Signs and Symptoms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Sedative dosage continuously administered during the measurement interval. [mg/kg/h] |
| From 90 minutes before to 10 minutes after encephalographic measurement |
| Dosage of continuously delivered central NMDA receptor active substances. | Sedative dosage continuously administered during the measurement interval. [mg/kg/h] | From 90 minutes before to 10 minutes after encephalographic measurement |
| Dosage of continuously delivered opioid based analgesia. | Analgetic dosage continuously administered during the measurement interval. [µg/kg/h] | From 90 minutes before to 10 minutes after encephalographic measurement |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |